Covered recipient · General Payments record
MUGDHA AGRAWAL
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2024
$7,801.56
- Reported across 383 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $839.61 | 33 |
| Education | $79.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $286.65 | 6 |
| ABBVIE INC. | $274.94 | 12 |
| Amgen Inc. | $222.67 | 8 |
| E.R. Squibb & Sons, L.L.C. | $53.24 | 3 |
| Acerta Pharma LLC | $30.81 | 2 |
| Lilly USA, LLC | $20.29 | 1 |
| UCB, Inc. | $16.69 | 1 |
| GlaxoSmithKline, LLC. | $14.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $12.76 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181556 | CMS |
| ABBVIE INC. | $16.28 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181558 | CMS |
| ABBVIE INC. | $11.30 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181560 | CMS |
| ABBVIE INC. | $15.13 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181562 | CMS |
| ABBVIE INC. | $11.79 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181564 | CMS |
| ABBVIE INC. | $16.48 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181566 | CMS |
| ABBVIE INC. | $16.40 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181568 | CMS |
| ABBVIE INC. | $13.75 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181570 | CMS |
| ABBVIE INC. | $15.84 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181572 | CMS |
| ABBVIE INC. | $20.55 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181574 | CMS |
| ABBVIE INC. | $12.20 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181576 | CMS |
| ABBVIE INC. | $112.46 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103181578 | CMS |
| Amgen Inc. | $16.26 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411019 | CMS |
| Amgen Inc. | $16.04 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411024 | CMS |
| Amgen Inc. | $121.41 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411039 | CMS |
| Amgen Inc. | $5.45 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411044 | CMS |
| Amgen Inc. | $15.32 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411027 | CMS |
| Amgen Inc. | $16.55 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411031 | CMS |
| Amgen Inc. | $16.42 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411047 | CMS |
| Amgen Inc. | $15.22 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115411035 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.07 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104781012 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.74 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105563268 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.09 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101599593 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.97 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101599590 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.18 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101599618 | CMS |
| GlaxoSmithKline, LLC. | $14.31 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116513235 | CMS |
| Janssen Biotech, Inc. | $16.58 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377726 | CMS |
| Janssen Biotech, Inc. | $16.56 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377397 | CMS |
| Janssen Biotech, Inc. | $79.99 | 04/30/2024 | Education | Undisputed | 01/23/2026 | 1078377074 | CMS |
| Janssen Biotech, Inc. | $16.58 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377771 | CMS |
| Janssen Biotech, Inc. | $16.11 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377444 | CMS |
| Janssen Biotech, Inc. | $140.83 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078377747 | CMS |
| Lilly USA, LLC | $20.29 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135260524 | CMS |
| UCB, Inc. | $16.69 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143157221 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.